Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

本申请是为了回应被确认为非CA-CA的特殊利益通知(NOSI)而提交的 20-052. 项目摘要 虽然几种创新和创造性的抗癌疗法已经显示出有希望的结果，但一个重要的 扩大它们的临床应用将需要合作努力来阐明耐药机制，开发肿瘤 敏感性，绘制癌症依赖图，发现新靶点，识别预测生物标记物，评估组合 治疗方法，并开发实时监测方法。利用尖端的多学科团队 方法，我们将支持NCI耐药和敏感网络(DRSN)了解和打击 肿瘤耐药的机制和开发肿瘤对抗癌治疗的敏感性。我们的战略是服务于 作为管理、通信、协作和分析中心，协调DRSN的整个网络 研究，重点是减少领域专业知识的障碍，提高DRSN调查人员的生产力， 保持高标准的数据协调和集成，设计和实施严格的 分析战略，并培养一个协作和支持性的研究社区。 已经组建了一支经验丰富的多学科团队，以实现五个具体目标：第一，我们将提供 以免疫肿瘤学为基础的用于协调DRSN活动的集中式管理基础设施 翻译网络数据管理与资源共享中心S运行良好 目前在NCI癌症登月计划的保护伞下协调网络研究的基础设施 主动权。第二，我们将积极推动DRSN，促进跨财团互动，我们将 利用IOTN DMRC在跨月球拍摄外展和生物导体方面的明显经验 数十年来在全社区参与方面的记录。第三，我们将提供多学科专业知识，以 支持DRSN协作研究，利用罗斯韦尔公园CCSG的四个共享资源： 生物统计学、生物信息学、数据库和生物储存库、生物分析、代谢组学和药物动力学。我们的 分析支持将配备专业的IT人员，并由经验丰富的抗癌治疗人员提供信息 研究团队。第四，我们将创新多组学数据集成方法，以增强DRSN的 研究能力，利用备受尊敬和非常成功的BioConductor项目。第五，我们将 向更广泛的社区传播在DRSN中开发的资源，充分释放DRSN的潜力 活动。综上所述，我们设想我们的CC将与DRSN组件密切合作，使我们能够 进行高效和创新的翻译研究，以满足相关的重大未得到满足的需求 致力于抗癌治疗，实现NCI癌症登月行动的期望和指导原则。

This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 20-052. Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi-disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno-Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well-functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly-successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.